Dignitana AB, world leader in clinically superior scalp cooling technology, will assume the complete operation from Sysmex Europe GmbH of their DigniLife scalp cooling division. The agreement is effective April 2018 and the transition with medical facilities will begin immediately.
Since June 2012, Sysmex Europe GmbH has been the exclusive distributor for the DigniCap Scalp Cooling System in the majority of European countries, marketing the device as DigniLife® – the innovative concept for successful scalp cooling. In addition to the FDA-cleared DigniCap® Scalp Cooling System, the DigniLife program includes customized services to support European healthcare professionals and patients using the scalp cooling treatment. Currently, Sysmex provides DigniLife to 70 medical facilities with 93 DigniCap units in Austria, Belgium, Czech Republic, France, Germany, Italy, Poland, Spain, Switzerland, The Netherlands, and Turkey.
“Over the past six years our collaborative partnership with Sysmex has been mutually beneficial,” said William Cronin, CEO of Dignitana AB. “Their dedicated efforts and significant resources supporting the DigniCap product have provided a substantial foundation for the device in Europe. As Dignitana transitions into our next phase of growth it makes great sense for us to expand on the momentum and success that Sysmex has created with the DigniCap device.“
“Sysmex is passionate about providing innovative solutions in healthcare, and working with Dignitana gave us the opportunity to do just that,” said Dr. Ines Gröner, Senior Vice President of Sysmex Europe GmbH. “Although we will now turn our focus to other aspects of our business, we anticipate maintaining a solid relationship with Dignitana and look forward to seeing their progress as they expand availability of this life-changing treatment to even more patients.”
Recognized internationally as a major quality-of-life medical advancement for cancer patients, the DigniCap® Scalp Cooling System was the first of its kind to be cleared by the FDA in 2015 for use by breast cancer patients. In July 2017, it became the only such device to receive FDA clearance for use by patients with solid tumor cancers.
Europe comprises only one-eighth of the total world population but has around one quarter of the global total of cancer cases with some 3.7 million new patients per year. Breast cancer is the most common cancer in European women with an approximately 500,000 new diagnoses per year (World Health Organization and European Breast Cancer Coalition).
About Sysmex Corporation
Sysmex Corporation, based in Kobe, Japan, is one of the international leading providers of solutions for the systematization of processes for medical laboratories, including laboratory diagnostics and laboratory automation. For 50 years Sysmex has been setting new standards with technology that contributes significantly to improvement in health: Shaping the Advancement of Healthcare. The Sysmex Business Unit Oncology is working on innovative solutions to improve and personalize cancer management with the aim to enhance the clinical workflows and increase patients’ comfort. The company has regional offices in North America, Latin America, Europe, China and Asia-Pacific region and employs more than 8,000 employees worldwide. Sysmex Corporation is listed on the Tokyo stock exchange. To learn more about Sysmex please visit www.sysmex-europe.com and www.sysmex.co.jp/en/
About Dignitana AB (publ)
Dignitana is a Swedish public company based in Lund and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on Nasdaq First North Stockholm and has appointed Erik Penser Bank as Certified Adviser. Headquartered in Dallas Texas, Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. DigniCap® is a patented scalp cooling system that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort.
For more information visit www.dignitana.se and www.dignicap.com
